Developer docs
API playgroundTry for free, no card

Search company profiles

Myomo

Full company profile

uuid0002ht3

Namestring
Myomo
Legal namestring
Myomo, Inc.
Websiteurl
myomo.com
Company typeenum
Public
Founded yearint
2006
Descriptiontext

Myomo is a publicly traded medical robotics company (NYSE American: MYO) that develops and commercializes the MyoPro product line, a family of FDA Class-2 powered upper-limb orthoses designed to restore arm and hand function in patients with stroke, brachial plexus injury, cerebral palsy, ALS, multiple sclerosis, and other neuromuscular conditions. The core technology uses non-invasive surface electromyography (EMG) sensors to detect the patient's own residual muscle signals, which are then amplified to drive small motors providing elbow flexion/extension, wrist movement, and hand grasping (including 3-jaw chuck grasp). The technology was originally developed at MIT and Harvard Medical School, with Myomo holding exclusive license to foundational MIT patents since spinning out in 2006. Current products include the MyoPro 2x (latest generation launched April 2025), MyoPro Motion-G, MyoPro Motion-W, and MyoPro 2+, supported by the Myomo Mobile App for remote EMG customization and the MyoConfig clinical software platform. Regulatory clearances span FDA, CE Mark, and Health Canada, with dedicated Medicare DMEPOS fee schedule codes L8701 and L8702.

The company generates revenue primarily through hardware sales of MyoPro devices at an average selling price of $58,800, with reimbursement sourced from Medicare Part B, commercial payers via an Elevance Health network participation agreement covering 80+ million lives, and international government health programs including German statutory health insurance. Distribution is hybrid: certified prosthetist and orthotist practices (300+ trained Certified Prosthetists Orthotists as of Q1 2025), an exclusive global partnership with Ottobock (the world market leader in technical orthopedics), Ottobock Care clinics nationwide, and regional international distributors across Australia/New Zealand, Italy, and the UK. The company also sells direct-to-consumer through its website, screening events in 20+ cities, and the MyoConnect clinician referral program. Recurring patient sources grew from 25% of revenue a year ago to 49% in Q1 2026, indicating a maturing revenue base weighted toward existing patient upgrades and replacements rather than first-time acquisition.

Myomo is headquartered in Burlington, Massachusetts, employs 101-250 people, and went public in June 2017 via a historic SEC Regulation A+ IPO on NYSE MKT. The company has subsequently raised additional capital through multiple public equity offerings (totaling approximately $36.4 million in 2017-2024) and a $17.5 million debt facility from Avenue Capital in November 2025, while remaining unprofitable with FY2025 EBITDA of approximately -$13.5 million on $40.9 million in revenue. Gross margins stand at 68.2% (Q1 2026), reflecting the hardware-intensive medical device cost structure.

Short descriptiontext

Myomo develops and markets the MyoPro, a powered upper-limb orthosis using non-invasive EMG sensors to restore arm and hand function for patients with stroke, brachial plexus injury, cerebral palsy, and other neuromuscular conditions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBurlington, United States
HQ citystring
Burlington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
powered orthotic devices, myoelectric arm braces, upper limb rehabilitation, stroke recovery devices, neuromuscular assistive technology
Industry3 codes
PRIMARYHLAHAMAC
Orthotics & Bracing (AFO/KAFO, Spinal, Soft Goods Supports)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Rehabilitation & Mobility Aids (DME)
SECONDARYHLAHAEAI
Orthotics & Bracing (Spinal/Lower/Upper Extremity Orthoses)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHSADAIAH
Hand & Upper Extremity Therapy (OT/CHT)
Home & Personal Services/Fitness, Wellness & Personal Training/Physical Therapy, Rehabilitation & Corrective Exercise
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Powered Orthotic Medical Devices
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model3 records
1MyoPro Device Sales
TypeHardware Sales
Description

Myomo generates revenue primarily through the sale of MyoPro powered arm orthoses to patients. The average selling price is approximately $58,800. Revenue recognition depends on insurance authorization and reimbursement, with growing recurring patient sources representing 49% of Q1 2026 revenue versus 25% a year ago.

myomo.com
2Insurance Reimbursement
TypeTransaction Fee
Description

Myomo derives significant revenue from insurance payer reimbursements including Medicare Part B, commercial insurance through network agreements (Elevance Health with 80+ million covered lives), and international government health programs (German statutory health insurance).

businesswire.com
3Digital Health Services
TypeSubscription Recurring
Description

With the launch of Myomo Mobile App, the company is building a connected digital ecosystem around its MyoPro device, capturing usage data for reimbursement support and product development.

stocktitan.net
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations
Pricing details1 tier
1MyoPro powered arm orthosis with average selling price of $58,800
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

The MyoPro is priced at an average selling price of $58,800. Medicare DMEPOS fee schedule rates apply for codes L8701 and L8702. Insurance coverage varies by payer; Myomo has network agreements with Elevance Health covering over 80 million lives and processes claims through HOMELINK's network of 1,200 payers.

in.investing.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1MyoPro
Description

The company's primary product line - powered upper-limb orthosis designed to help regain function in arms and hands paralyzed by stroke, brachial plexus injury, cerebral palsy, or other neuromuscular conditions

myomo.com
+7 more records
Core offering1 text field

Myomo designs, manufactures, and sells the MyoPro family of powered upper-limb orthoses that use non-invasive surface EMG sensors to detect and amplify a patient's own muscle signals, driving small motors to assist with elbow flexion/extension, wrist movement, and hand grasping. The devices are prescribed for individuals with arm paralysis or weakness from stroke, brachial plexus injury, cerebral palsy, and other neuromuscular conditions, fitted by certified prosthetists/orthotists, and reimbursed primarily through Medicare Part B, commercial insurance (e.g., Elevance Health), and international health systems.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 47% average improvement in Fugl-Meyer Scale scores for chronic stroke patients using MyoPro
+4 more records
Product overview1 text field

Myomo is a medical robotics company that develops and markets the MyoPro product line—a family of powered upper-limb orthoses designed to restore function to paralyzed or weakened arms for patients with neurological disorders including stroke, brachial plexus injury, traumatic brain/spinal cord injury, ALS, cerebral palsy, and other neuromuscular conditions. The core MyoPro products (MyoPro 2x, Motion-G, Motion-W) are wearable braces that detect the patient's own EMG signals through non-invasive sensors, amplifying them to drive motors that assist with arm and hand movement. The product portfolio includes current generations (MyoPro 2x, MyoPro 2+) and legacy versions, supported by the Myomo Mobile App for remote device management and MyoConnect/MyoCare service programs. The MyoPro is currently the only marketed device in the U.S. that uses EMG sensing to restore activities of daily living.

Product and service5 records
1MyoPro 2x
CategoryPowered Upper-Limb Orthosis
Description

Latest generation powered arm orthosis using EMG sensors to detect muscle signals and drive motors, restoring function for activities of daily living in users whose arms are paralyzed or weakened by stroke, brachial plexus injury, cerebral palsy, or other neuromuscular conditions.

2MyoPro 2+
CategoryPowered Upper-Limb Orthosis
Description

Powered upper-limb orthosis version with enhanced features designed for patients with neurological disorders and upper-limb paralysis.

3MyoPro Motion-G
CategoryPowered Upper-Limb Orthosis
Description

Powered orthosis providing elbow flexion/extension and powered grasping (3-jaw chuck grasp capability) for individuals with upper extremity paresis; detects EMG signals in bicep/tricep and forearm to enable voluntary control of partially paralyzed arms.

4MyoPro Motion-W
CategoryPowered Upper-Limb Orthosis
Description

Elbow-wrist-hand orthosis variant with articulating handpiece providing wrist and hand support for patients with upper limb weakness or partial paralysis.

5Myomo Mobile App
CategoryDigital Health Software
Description

Mobile application for clinicians and patients using the MyoPro, enabling remote customization of EMG settings, real-time visualization of muscle activity, and capture of usage data to support reimbursement claims and product development.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-09
Description

Myomo entered into network participation agreements with Elevance Health covering Anthem-affiliated Commercial, Medicare Advantage, and Medicaid plans effective through 2026. The agreements add 45 million medical members, expanding coverage to over 80 million covered lives for MyoPro orthoses.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-02-19
Description

Myomo signed agreement with HOMELINK enabling the company to bill in-network with 1,200 payers for processing out-of-network claims for MyoPro powered orthosis.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2019-12-16
Description

Myomo partnered with Hobbs Rehabilitation to provide services supporting MyoPro users in the UK. Hobbs neurological physiotherapists and occupational therapists work with patients using MyoPro family of myoelectric orthotics.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2019-05-01
Description

Myomo signed agreement with NMO to offer MyoPro across Australia and New Zealand markets.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2019-03-18
Description

Myomo signed agreement with PAR, a unit of Progettiamo Autonomia headquartered in Reggio Emilia, Italy with 17 offices nationwide, to offer MyoPro in Italy.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2016-12-19
Description

Ottobock, a world market leader in technical orthopedics, entered into an exclusive global distribution agreement for MyoPro starting January 1, 2017. The partnership enables Ottobock to address unmet needs of individuals with upper extremity paralysis through Myomo's myoelectric orthotic technology. Myomo expanded availability through Ottobock Care clinics in 2026.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developer of wearable robotic exoskeletons for rehabilitation and mobility. Comparable as a publicly traded rehabilitation robotics company targeting stroke and spinal cord injury, addressing overlapping patient populations with a different (lower-limb) product focus.

2Bionik Laboratories
TypeEmerging player
Description

Robotic rehabilitation technology company focused on upper and lower extremity therapy. Comparable as a smaller, R&D-stage peer pursuing similar neuro-rehabilitation applications with overlapping target patient populations.

TypeDirect peer
Description

Largest U.S. provider of orthotic and prosthetic clinical services. Hanger's network of O&P patient-care centers is the same clinical channel through which MyoPro is fitted and reimbursed, making it the most relevant service-side peer.

TypeDirect peer
Description

Global leader in orthotics and prosthetics, including upper-limb solutions. Directly comparable product portfolio (bracing and prosthetic components) and overlapping clinical channels make it Myomo's closest public peer in non-invasive orthotic technology.

TypeDirect peer
Description

Specialist in upper-extremity rehabilitation devices for stroke survivors (e.g., SaeboGlove, SaeboReach). Directly comparable in target patient (stroke-related hand/arm impairment), clinical channel (OT/PT), and reimbursement-driven commercial model.

TypeBroad incumbent
Description

World market leader in technical orthopedics and Myomo's exclusive global distribution partner. Comparable in upper-limb orthotics and prosthetics, with a much broader portfolio across mobility, prosthetics, and patient care; operates as both partner and adjacent competitor.

TypeBroad incumbent
Description

Industrial motion and control conglomerate that also sells the Indego powered orthosis through its Human Motion & Control business. Comparable as a broad incumbent entering the powered lower-extremity orthosis/exoskeleton category with similar payer and clinical dynamics.

TypeDirect peer
Description

Pioneer in wearable robotic exoskeletons for spinal cord injury and stroke rehabilitation. Comparable as a small-cap public peer in powered rehabilitation wearables, with similar payer-reimbursement dynamics and clinical-evidence requirements.

TypeDirect peer
Description

Manufacturer of prosthetic and orthotic components with global O&P distribution. Comparable in product scope (upper-limb orthotics/prosthetic components) and clinical channel, though without Myomo's powered/myoelectric specialization.

TypeEmerging player
Description

Developer of EMG-driven neurostimulation devices (e.g., for diaphragm pacing). Comparable as a niche EMG-based neurotechnology company working in the broader neuromuscular rehabilitation space with similar clinical and regulatory pathways.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Myomo

Powered Orthotic Medical Devicesmyomo.com

Myomo develops and markets the MyoPro, a powered upper-limb orthosis using non-invasive EMG sensors to restore arm and hand function for patients with stroke, brachial plexus injury, cerebral palsy, and other neuromuscular conditions.

What Myomo does

Myomo is a publicly traded medical robotics company (NYSE American: MYO) that develops and commercializes the MyoPro product line, a family of FDA Class-2 powered upper-limb orthoses designed to restore arm and hand function in patients with stroke, brachial plexus injury, cerebral palsy, ALS, multiple sclerosis, and other neuromuscular conditions. The core technology uses non-invasive surface electromyography (EMG) sensors to detect the patient's own residual muscle signals, which are then amplified to drive small motors providing elbow flexion/extension, wrist movement, and hand grasping (including 3-jaw chuck grasp). The technology was originally developed at MIT and Harvard Medical School, with Myomo holding exclusive license to foundational MIT patents since spinning out in 2006. Current products include the MyoPro 2x (latest generation launched April 2025), MyoPro Motion-G, MyoPro Motion-W, and MyoPro 2+, supported by the Myomo Mobile App for remote EMG customization and the MyoConfig clinical software platform. Regulatory clearances span FDA, CE Mark, and Health Canada, with dedicated Medicare DMEPOS fee schedule codes L8701 and L8702.

The company generates revenue primarily through hardware sales of MyoPro devices at an average selling price of $58,800, with reimbursement sourced from Medicare Part B, commercial payers via an Elevance Health network participation agreement covering 80+ million lives, and international government health programs including German statutory health insurance. Distribution is hybrid: certified prosthetist and orthotist practices (300+ trained Certified Prosthetists Orthotists as of Q1 2025), an exclusive global partnership with Ottobock (the world market leader in technical orthopedics), Ottobock Care clinics nationwide, and regional international distributors across Australia/New Zealand, Italy, and the UK. The company also sells direct-to-consumer through its website, screening events in 20+ cities, and the MyoConnect clinician referral program. Recurring patient sources grew from 25% of revenue a year ago to 49% in Q1 2026, indicating a maturing revenue base weighted toward existing patient upgrades and replacements rather than first-time acquisition.

Myomo is headquartered in Burlington, Massachusetts, employs 101-250 people, and went public in June 2017 via a historic SEC Regulation A+ IPO on NYSE MKT. The company has subsequently raised additional capital through multiple public equity offerings (totaling approximately $36.4 million in 2017-2024) and a $17.5 million debt facility from Avenue Capital in November 2025, while remaining unprofitable with FY2025 EBITDA of approximately -$13.5 million on $40.9 million in revenue. Gross margins stand at 68.2% (Q1 2026), reflecting the hardware-intensive medical device cost structure.

Myomo firmographics

Firmographics
Name
Myomo
Legal name
Myomo, Inc.
Website
https://myomo.com
Company type
Public
Founded year
2006
Operating status
Operating
Headcount range
101–250 employees
Short description
Myomo develops and markets the MyoPro, a powered upper-limb orthosis using non-invasive EMG sensors to restore arm and hand function for patients with stroke, brachial plexus injury, cerebral palsy, and other neuromuscular conditions.
Ownership category
akta.pro rank

Myomo industry classification

Industry
Product category
Powered Orthotic Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAMAC
Orthotics & Bracing (AFO/KAFO, Spinal, Soft Goods Supports)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Rehabilitation & Mobility Aids (DME)
SECONDARYHLAHAEAI
Orthotics & Bracing (Spinal/Lower/Upper Extremity Orthoses)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHSADAIAH
Hand & Upper Extremity Therapy (OT/CHT)
Home & Personal Services/Fitness, Wellness & Personal Training/Physical Therapy, Rehabilitation & Corrective Exercise

Keywords

  • Powered orthotic devices
  • Myoelectric arm braces
  • Upper limb rehabilitation
  • Stroke recovery devices
  • Neuromuscular assistive technology

Where Myomo is headquartered

Location

Headquarters

HQ city
Burlington
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Myomo business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. MyoPro Device Sales: Myomo generates revenue primarily through the sale of MyoPro powered arm orthoses to patients. The average selling price is approximately $58,800. Revenue recognition depends on insurance authorization and reimbursement, with growing recurring patient sources representing 49% of Q1 2026 revenue versus 25% a year ago.
  2. Insurance Reimbursement: Myomo derives significant revenue from insurance payer reimbursements including Medicare Part B, commercial insurance through network agreements (Elevance Health with 80+ million covered lives), and international government health programs (German statutory health insurance).
  3. Digital Health Services: With the launch of Myomo Mobile App, the company is building a connected digital ecosystem around its MyoPro device, capturing usage data for reimbursement support and product development.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goMyoPro powered arm orthosis with average selling price of $58,800

Go-to-market motion4 records

Distribution channels6 records

Marketing channels7 records

Myomo product offering

Product offering

Core offering

Myomo designs, manufactures, and sells the MyoPro family of powered upper-limb orthoses that use non-invasive surface EMG sensors to detect and amplify a patient's own muscle signals, driving small motors to assist with elbow flexion/extension, wrist movement, and hand grasping. The devices are prescribed for individuals with arm paralysis or weakness from stroke, brachial plexus injury, cerebral palsy, and other neuromuscular conditions, fitted by certified prosthetists/orthotists, and reimbursed primarily through Medicare Part B, commercial insurance (e.g., Elevance Health), and international health systems.

Product overview

Myomo is a medical robotics company that develops and markets the MyoPro product line—a family of powered upper-limb orthoses designed to restore function to paralyzed or weakened arms for patients with neurological disorders including stroke, brachial plexus injury, traumatic brain/spinal cord injury, ALS, cerebral palsy, and other neuromuscular conditions. The core MyoPro products (MyoPro 2x, Motion-G, Motion-W) are wearable braces that detect the patient's own EMG signals through non-invasive sensors, amplifying them to drive motors that assist with arm and hand movement. The product portfolio includes current generations (MyoPro 2x, MyoPro 2+) and legacy versions, supported by the Myomo Mobile App for remote device management and MyoConnect/MyoCare service programs. The MyoPro is currently the only marketed device in the U.S. that uses EMG sensing to restore activities of daily living.

Differentiator

Problem solved

Functional benefit

Brands

  • MyoPro: The company's primary product line - powered upper-limb orthosis designed to help regain function in arms and hands paralyzed by stroke, brachial plexus injury, cerebral palsy, or other neuromuscular conditions
  • MyoPro Motion-G
  • MyoPro Motion-W
  • MyoPro 2x
  • MyoConnect
  • MyoCare
  • Myomo Mobile App
  • MyoPro For Veterans

Products and services

  • MyoPro 2x Latest generation powered arm orthosis using EMG sensors to detect muscle signals and drive motors, restoring function for activities of daily living in users whose arms are paralyzed or weakened by stroke, brachial plexus injury, cerebral palsy, or other neuromuscular conditions.
  • MyoPro 2+ Powered upper-limb orthosis version with enhanced features designed for patients with neurological disorders and upper-limb paralysis.
  • MyoPro Motion-G Powered orthosis providing elbow flexion/extension and powered grasping (3-jaw chuck grasp capability) for individuals with upper extremity paresis; detects EMG signals in bicep/tricep and forearm to enable voluntary control of partially paralyzed arms.
  • MyoPro Motion-W Elbow-wrist-hand orthosis variant with articulating handpiece providing wrist and hand support for patients with upper limb weakness or partial paralysis.
  • Myomo Mobile App Mobile application for clinicians and patients using the MyoPro, enabling remote customization of EMG settings, real-time visualization of muscle activity, and capture of usage data to support reimbursement claims and product development.

Quantifiable outcome

  • 47% average improvement in Fugl-Meyer Scale scores for chronic stroke patients using MyoPro
  • +4 more outcomes

Companies that use Myomo

Customer profile

Named customers6 records

Segments6 records

Ideal customer profiles4 records

Myomo technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Myomo partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Elevance HealthcoreChannel Partner/ Reseller/ Distributor · 9 March 2026Myomo entered into network participation agreements with Elevance Health covering Anthem-affiliated Commercial, Medicare Advantage, and Medicaid plans effective through 2026. The agreements add 45 million medical members, expanding coverage to over 80 million covered lives for MyoPro orthoses.
  • HOMELINKminorChannel Partner/ Reseller/ Distributor · 19 February 2020Myomo signed agreement with HOMELINK enabling the company to bill in-network with 1,200 payers for processing out-of-network claims for MyoPro powered orthosis.
  • Hobbs RehabilitationminorChannel Partner/ Reseller/ Distributor · 16 December 2019Myomo partnered with Hobbs Rehabilitation to provide services supporting MyoPro users in the UK. Hobbs neurological physiotherapists and occupational therapists work with patients using MyoPro family of myoelectric orthotics.
  • NeuroMuscular Orthotics Pty Ltd (NMO)minorChannel Partner/ Reseller/ Distributor · 1 May 2019Myomo signed agreement with NMO to offer MyoPro across Australia and New Zealand markets.
  • Progettiamo Autonomia Robotics (PAR)minorChannel Partner/ Reseller/ Distributor · 18 March 2019Myomo signed agreement with PAR, a unit of Progettiamo Autonomia headquartered in Reggio Emilia, Italy with 17 offices nationwide, to offer MyoPro in Italy.
  • OttobockcoreChannel Partner/ Reseller/ Distributor · 19 December 2016Ottobock, a world market leader in technical orthopedics, entered into an exclusive global distribution agreement for MyoPro starting January 1, 2017. The partnership enables Ottobock to address unmet needs of individuals with upper extremity paralysis through Myomo's myoelectric orthotic technology. Myomo expanded availability through Ottobock Care clinics in 2026.

Scale indicators10 records

Recent moves10 records

Expansion highlights6 records

Myomo competitors and assessment

Company assessment

Direct peers

  • Ekso Bionics: Developer of wearable robotic exoskeletons for rehabilitation and mobility. Comparable as a publicly traded rehabilitation robotics company targeting stroke and spinal cord injury, addressing overlapping patient populations with a different (lower-limb) product focus.
  • Hanger, Inc. Largest U.S. provider of orthotic and prosthetic clinical services. Hanger's network of O&P patient-care centers is the same clinical channel through which MyoPro is fitted and reimbursed, making it the most relevant service-side peer.
  • Össur: Global leader in orthotics and prosthetics, including upper-limb solutions. Directly comparable product portfolio (bracing and prosthetic components) and overlapping clinical channels make it Myomo's closest public peer in non-invasive orthotic technology.
  • Saebo: Specialist in upper-extremity rehabilitation devices for stroke survivors (e.g., SaeboGlove, SaeboReach). Directly comparable in target patient (stroke-related hand/arm impairment), clinical channel (OT/PT), and reimbursement-driven commercial model.
  • ReWalk Robotics: Pioneer in wearable robotic exoskeletons for spinal cord injury and stroke rehabilitation. Comparable as a small-cap public peer in powered rehabilitation wearables, with similar payer-reimbursement dynamics and clinical-evidence requirements.
  • Fillauer: Manufacturer of prosthetic and orthotic components with global O&P distribution. Comparable in product scope (upper-limb orthotics/prosthetic components) and clinical channel, though without Myomo's powered/myoelectric specialization.

Emerging players

  • Bionik Laboratories: Robotic rehabilitation technology company focused on upper and lower extremity therapy. Comparable as a smaller, R&D-stage peer pursuing similar neuro-rehabilitation applications with overlapping target patient populations.
  • Synapse Biomedical: Developer of EMG-driven neurostimulation devices (e.g., for diaphragm pacing). Comparable as a niche EMG-based neurotechnology company working in the broader neuromuscular rehabilitation space with similar clinical and regulatory pathways.

Broad incumbents

  • Ottobock: World market leader in technical orthopedics and Myomo's exclusive global distribution partner. Comparable in upper-limb orthotics and prosthetics, with a much broader portfolio across mobility, prosthetics, and patient care; operates as both partner and adjacent competitor.
  • Parker Hannifin: Industrial motion and control conglomerate that also sells the Indego powered orthosis through its Human Motion & Control business. Comparable as a broad incumbent entering the powered lower-extremity orthosis/exoskeleton category with similar payer and clinical dynamics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Myomo social profiles

Digital presence

Myomo compliance and trust

Trust signal

Compliance8 records

Myomo financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Myomo leadership team

Management profile

Number of profiles

Profiles5 records

Myomo subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Myomo funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Myomo M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Myomo

What does Myomo do?

Myomo designs, manufactures, and sells the MyoPro family of powered upper-limb orthoses that use non-invasive surface EMG sensors to detect and amplify a patient's own muscle signals, driving small motors to assist with elbow flexion/extension, wrist movement, and hand grasping. The devices are prescribed for individuals with arm paralysis or weakness from stroke, brachial plexus injury, cerebral palsy, and other neuromuscular conditions, fitted by certified prosthetists/orthotists, and reimbursed primarily through Medicare Part B, commercial insurance (e.g., Elevance Health), and international health systems.

Is Myomo a public or private company?

Myomo is a public company. It is classified as public and is currently operating.

When was Myomo founded?

Myomo was founded in 2006. It employs 101 to 250 people.

Where is Myomo based?

Myomo is headquartered in Burlington, United States, in the North America region.

How does Myomo make money?

Three revenue lines are on record. MyoPro Device Sales are the primary driver. The others are insurance Reimbursement and digital Health Services.

Who are Myomo's main competitors?

Direct peers on record are Ekso Bionics, Hanger, Inc., Össur, Saebo, ReWalk Robotics and Fillauer. Emerging players are Bionik Laboratories and Synapse Biomedical. Broad incumbents are Ottobock and Parker Hannifin.

Does Myomo have an API?

No public API is recorded for Myomo.

What industry is Myomo in?

Myomo's product category is Powered Orthotic Medical Devices. Its primary akta.pro industry code is HLAHAMAC, Orthotics & Bracing (AFO/KAFO, Spinal, Soft Goods Supports), with a secondary code of HLAHAEAI, Orthotics & Bracing (Spinal/Lower/Upper Extremity Orthoses). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaMyomo narrows 2026 revenue guidance to $46M-$47M as it expects modest sequential gross margin improvement in Q4 (NYSE:MYO)Myomo reported Q3 2026 revenue of $12.3 million, up 22% year-over-year, with gross margin at 71.3% and adjusted EBITDA at breakeven. The company narrowed its 2026 revenue guidance to $46 million to $47 million, expecting modest sequential gross margin improvement in Q4.AInvestMyomo (MYO) shares rise 11.35% intraday after Q2 earnings beat and raised guidanceMyomo shares rose 11.35% intraday after reporting Q2 2026 earnings that beat revenue estimates and raised full-year guidance. Revenue came in at $11.7 million versus $10.29 million expected, gross margins improved to 72.1%, and net loss narrowed to $0.09 per share.Investing.comMyomo at H.C. Wainwright conference: referral shift drives growth By Investing.comMyomo outlined its growth strategy at the H.C. Wainwright conference, citing Medicare coverage as a turning point that doubled revenue over two years. The company shifted to referral-based growth, with gross margin rising to 72% and 2026 revenue guidance of $45–47 million. It expects to reach free-cash-flow breakeven at about $15 million quarterly.Markets DailyMyomo, Inc. (NYSEAMERICAN:MYO) Sees Significant Decline in Short InterestMyomo's short interest fell 39.1% to 1,124,493 shares as of August 14th, with 3.2% of shares short sold. Insiders Harry Kovelman and Thomas Kirk made trades, and analysts maintain a Buy rating with a $10 price target. The company reported Q2 EPS of -$0.09, beating estimates, but remains unprofitable.AInvestMyomo's Q2 Beat: Margin Climb and Raised Guidance Point to Real Operating ProgressMyomo reported Q2 revenue of $11.7 million, beating consensus estimates by $1.4 million and narrowing operating losses to $2.3 million from $4.6 million year-over-year, while raising Q3 2026 revenue guidance to $12 million and full-year outlook to $45–47 million. Gross margin expanded to 72.1% from 62.7% while operating expenses rose less than 1%, demonstrating improved operational leverage for the medical device company. The company also highlighted structural progress with recurring patient sources accounting for 53% of revenue, up from 26% a year earlier and ahead of schedule.MarketBeatMyomo Q2 Earnings Call HighlightsMyomo reported second-quarter 2026 revenue of $11.7 million, up 21% year over year, driven by a 2% increase in average selling price to approximately $55,500 and a 19% rise in recognized revenue units to 211 MyoPro devices. The company expanded its referral strategy, with recurring patient sources accounting for 53% of revenue, doubling from 26% a year earlier, while gross margin improved to 72.1% from 62.7% and operating loss narrowed to $2.3 million from $4.6 million. Myomo raised its full-year revenue guidance to $45 million to $47 million from prior guidance of $43 million to $46 million.MarketBeatMyomo Q2 Earnings Call HighlightsMyomo reported second-quarter 2026 revenue of $11.7 million, up 21% year-over-year, driven by a 19% increase in recognized revenue units to 211 MyoPro devices and a 2% rise in average selling price to approximately $55,500. The wearable robotics company achieved 53% recurring patient-sourced revenue, doubling from the prior year and reaching its 50% objective six months ahead of schedule, while gross margin expanded to 72.1% from 62.7%. Myomo raised its full-year revenue guidance to $45–47 million from $43–46 million and expects Q3 revenue of $11.5–12 million.Medical BuyerMyomo revenue up 21% to USD 11.7M in Q2 2026Myomo, Inc. reported Q2 2026 revenue of $11.7 million, up 21% year-over-year, with the company recognizing revenue on 211 MyoPro units, a 19% increase driven by higher volume in Direct Billing and O&P sales channels. Gross margin expanded to 72.1% from 62.7%, while adjusted EBITDA loss improved 79% to $0.8 million, and operating expenses remained roughly flat at $10.7 million. The company raised its full-year revenue guidance to $45–47 million and expects third quarter revenue of $11.5–12.0 million.YahooMyomo Inc (MYO) (Q2 2026) Earnings Call Highlights: Record Orders and Margin Expansion Drive ...Myomo Inc reported Q2 2026 revenue of $11.7 million, up 21% year-over-year, with record quarterly orders of 255 MyoPro units driven by expanding market access and recurring patient sources now representing 53% of total revenue. The company achieved significant margin expansion with gross margin improving to 72.1% from 62.7%, while operating loss improved to $2.3 million from $4.6 million and adjusted EBITDA loss narrowed by 79% year-over-year. Myomo raised its full-year 2026 revenue guidance to $45-47 million from the previous range of $43-46 million.Seeking AlphaMyomo expects $45M-$47M full-year revenue while targeting second-half cash burn below $2M (NYSE:MYO)Myomo, Inc. expects full-year revenue between $45 million and $47 million while targeting cash burn below $2 million for the second half of 2026. The company reported a 21% year-over-year revenue increase for Q2 2026, reaching $11.7 million, and noted that recurring patient sources now account for 53% of total revenue. Myomo also highlighted ongoing momentum in its MyoConnect program and progress in expanding referral infrastructure.